July 2026

LINKER-AL2 shows linvoseltamab delivers rapid, deep responses in relapsed AL amyloidosis, addressing major unmet need with off-the-shelf access and a manageable safety profile.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

Early data for LINKER-AL2 show linvoseltamab drives rapid and deep responses following relapse after frontline treatment for AL amyloidosis, which has no approved therapies.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed or refractory multiple myeloma, offering hope when IMiDs stop working.

ASCO highlights MorningSun results: subcutaneous mosunetuzumab offers a chemotherapy-free option for elderly patients with DLBCL, improving quality of life beyond R-CHOP.